A 'molecular volume control' may one day be used to manipulate enzyme activity in order control the development and treatment of cancer, according to research at the Universities of Dundee and Bath.
Jan 5, 2017
0
1
When tumour cells no longer degrade themselves, cancer may develop. Using black skin cancer as an example, Bern Researchers have now shown that a protein plays an important role in the process of degradation of tumour cells. ...
Sep 12, 2013
0
0
A side-by-side comparison of lung metastases showing the control antibody on the left and the podocalyxin antibody on the right. Researchers developed the podocalyxin antibody and found that it slowed tumour growth and spread.
Apr 10, 2015
0
18
Adding trastuzumab (trade name Herceptin) to the treatment offered to women who have HER2-positive breast cancer, significantly increases the chance of life being prolonged, and reduces the chance of tumours reappearing once ...
Apr 17, 2012
0
0
Researchers funded by the Medical Research Council (MRC) have shown that when the metabolite fumarate accumulates in a hereditary form of renal cancer it leads to an epigenetic reprogramming that drives cancer, according ...
Aug 31, 2016
0
3
The research, which has been published in the highly-regarded journal Molecular Cancer Therapeutics, suggests that peloruside A—a substance produced by the marine sponge Mycale henscheli, found mostly in Pelorus Sound—has ...
Jul 7, 2015
1
44
Researchers at McGill University are hopeful that the identification of the origin and a specific gene needed for tumor growth could lead to new therapeutics to treat a deadly brain cancer that arises in teens and young adults. ...
Dec 15, 2020
0
47
Lung cancer patients who are treated with radiotherapy can develop an inflammation of the lung tissue called pneumonitis; this can limit the dose of radiation they can receive and severe forms of pneumonitis, if left untreated, ...
May 5, 2017
0
3
(Medical Xpress) -- Researchers at Imperial College London have discovered a molecule that plays an important role in driving prostate cancer growth, and could be a target for new therapies.
Jul 3, 2012
0
0
The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with ...
Jan 8, 2019
0
4
